EU Medical Director
Amgen Biosimilars, Oncology
Jane Hippenmeyer was appointed Director of Scientific Affairs Amgen Biosimilars Europe in March 2016. In this role she is responsible for the creation of Scientific Affairs structures in European affiliate countries, to prepare for the launch of Amgen Biosimilars in Oncology and Inflammation. Jane is additional responsible for the execution of Scientific Affairs educational initiatives, advisory boards, medical society engagement and internal and external education on Amgen Biosimilars. Jane has been with Amgen Europe since 2004, when she joined the Medical Communications team. She has worked on the launch of several of Amgen's Oncology Biologics within Europe, most recently working on Blinatumomab (Blincyto). Prior to joining the Pharmaceutical Industry, Jane worked as Director of Drug Information Service at Memorial Sloan-Kettering Cancer Center, where she oversaw the hospital formulary decisions. Jane holds a Bachelor of Science in Pharmacy from the University of Illinois, Chicago and her Doctorate of Pharmacy from University of the Sciences in Philadelphia.